Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Mouth Neoplasms 1

Interventions

pembrolizumab 65Cisplatin 42Cetuximab 36Radiotherapy 28Nivolumab 26Paclitaxel 22Carboplatin 22Docetaxel 20durvalumab 14Radiotherapy, Intensity-Modulated 12Fluorouracil 12Cyclophosphamide 11tremelimumab 9Gemcitabine 9Ipilimumab 8fludarabine 7avelumab 7Erlotinib Hydrochloride 7toripalimab 6epacadostat 6cemiplimab 6Radiosurgery 6Interleukin-2 6Capecitabine 6Bevacizumab 6spartalizumab 5Celecoxib 5zalutumumab 4tislelizumab 4fludarabine phosphate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Calcitriol × Head & Neck × Clear all
NCT00953849 2017-03-07

Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity

VA Office of Research and Development

Phase 1/2 Completed
21 enrolled 10 charts
Head & Neck

Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡